WO2004106369A3 - Complement inhibitors from ticks - Google Patents

Complement inhibitors from ticks Download PDF

Info

Publication number
WO2004106369A3
WO2004106369A3 PCT/GB2004/002341 GB2004002341W WO2004106369A3 WO 2004106369 A3 WO2004106369 A3 WO 2004106369A3 GB 2004002341 W GB2004002341 W GB 2004002341W WO 2004106369 A3 WO2004106369 A3 WO 2004106369A3
Authority
WO
WIPO (PCT)
Prior art keywords
complement inhibitors
ticks
complement
relates
inhibitors
Prior art date
Application number
PCT/GB2004/002341
Other languages
French (fr)
Other versions
WO2004106369A2 (en
Inventor
Miles Andrew Nunn
Original Assignee
Evolutec Ltd
Miles Andrew Nunn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312619A external-priority patent/GB0312619D0/en
Priority claimed from GB0327386A external-priority patent/GB0327386D0/en
Priority to US10/558,937 priority Critical patent/US7884188B2/en
Priority to AU2004242759A priority patent/AU2004242759B2/en
Priority to EP04735758A priority patent/EP1629098B1/en
Priority to BRPI0410876A priority patent/BRPI0410876B8/en
Priority to CA2526083A priority patent/CA2526083C/en
Priority to JP2006508386A priority patent/JP4772667B2/en
Priority to DE602004020334T priority patent/DE602004020334D1/en
Application filed by Evolutec Ltd, Miles Andrew Nunn filed Critical Evolutec Ltd
Priority to NZ544163A priority patent/NZ544163A/en
Priority to MXPA05012880A priority patent/MXPA05012880A/en
Priority to CN200480015178.8A priority patent/CN1798841B/en
Publication of WO2004106369A2 publication Critical patent/WO2004106369A2/en
Publication of WO2004106369A3 publication Critical patent/WO2004106369A3/en
Priority to HK06105580.9A priority patent/HK1085511A1/en
Priority to US12/931,640 priority patent/US8993264B2/en
Priority to US14/624,909 priority patent/US9834585B2/en
Priority to US15/679,425 priority patent/US20180127472A1/en
Priority to US17/569,374 priority patent/US20220363726A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43552—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects
    • G01N2333/43556—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects from ticks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/42—Poisoning, e.g. from bites or stings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)

Abstract

The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases.
PCT/GB2004/002341 2003-06-02 2004-06-02 Complement inhibitors from ticks WO2004106369A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
MXPA05012880A MXPA05012880A (en) 2003-06-02 2004-06-02 Complement inhibitors from ticks.
CN200480015178.8A CN1798841B (en) 2003-06-02 2004-06-02 Complement inhibitors from ticks
NZ544163A NZ544163A (en) 2003-06-02 2004-06-02 Complement inhibitors
AU2004242759A AU2004242759B2 (en) 2003-06-02 2004-06-02 Complement inhibitors from ticks
EP04735758A EP1629098B1 (en) 2003-06-02 2004-06-02 Complement inhibitors from ticks
BRPI0410876A BRPI0410876B8 (en) 2003-06-02 2004-06-02 composition, fusion protein, cdna molecule, vector, recombinant prokaryotic host cell, method for making a complement inhibitor molecule, and uses of a composition and a fusion protein
CA2526083A CA2526083C (en) 2003-06-02 2004-06-02 Complement inhibitors
JP2006508386A JP4772667B2 (en) 2003-06-02 2004-06-02 Complement inhibitor
DE602004020334T DE602004020334D1 (en) 2003-06-02 2004-06-02 COMPLEMENT INHIBITORS FROM TICKS
US10/558,937 US7884188B2 (en) 2003-06-02 2004-06-02 Complement inhibitors
HK06105580.9A HK1085511A1 (en) 2003-06-02 2006-05-15 Complement inhibitors from ticks
US12/931,640 US8993264B2 (en) 2003-06-02 2011-02-07 Complement inhibitors
US14/624,909 US9834585B2 (en) 2003-06-02 2015-02-18 Method of inhibiting C5 cleavage
US15/679,425 US20180127472A1 (en) 2003-06-02 2017-08-17 Method of inhibiting c5 cleavage
US17/569,374 US20220363726A1 (en) 2003-06-02 2022-01-05 Method of Inhibiting C5 Cleavage

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0312619A GB0312619D0 (en) 2003-06-02 2003-06-02 Complement inhibitors
GB0312619.0 2003-06-02
GB0327386.9 2003-11-25
GB0327386A GB0327386D0 (en) 2003-11-25 2003-11-25 Complement inhibitors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/558,937 A-371-Of-International US7884188B2 (en) 2003-06-02 2004-06-02 Complement inhibitors
US12/931,640 Continuation US8993264B2 (en) 2003-06-02 2011-02-07 Complement inhibitors

Publications (2)

Publication Number Publication Date
WO2004106369A2 WO2004106369A2 (en) 2004-12-09
WO2004106369A3 true WO2004106369A3 (en) 2005-02-17

Family

ID=33492257

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/002341 WO2004106369A2 (en) 2003-06-02 2004-06-02 Complement inhibitors from ticks

Country Status (13)

Country Link
US (5) US7884188B2 (en)
EP (1) EP1629098B1 (en)
JP (1) JP4772667B2 (en)
AT (1) ATE427356T1 (en)
AU (1) AU2004242759B2 (en)
BR (1) BRPI0410876B8 (en)
CA (1) CA2526083C (en)
DE (1) DE602004020334D1 (en)
ES (1) ES2324993T3 (en)
HK (1) HK1085511A1 (en)
MX (1) MXPA05012880A (en)
NZ (1) NZ544163A (en)
WO (1) WO2004106369A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526083C (en) * 2003-06-02 2017-01-17 Evolutec Limited Complement inhibitors
US7999082B2 (en) 2004-02-10 2011-08-16 National Jewish Medical And Research Center Anti-factor B antibodies
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
CN101227924A (en) 2005-05-26 2008-07-23 科罗拉多大学评议会 Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
EP1959991B1 (en) * 2005-12-12 2013-03-20 AC Immune S.A. Therapeutic vaccine
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
WO2008029169A2 (en) * 2006-09-08 2008-03-13 Varleigh Limited Method of treating respiratory disorders
US8580735B2 (en) * 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
EP2565207A3 (en) 2007-03-14 2013-06-12 Alexion Cambridge Corporation Humaneered Anti-Factor B Antibody
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
US20090324585A1 (en) * 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
CN101928709B (en) * 2009-06-24 2012-05-23 中国农业科学院上海兽医研究所 Gene sequence, recombinant expression and application of hyalomma asiaticum histamine binding protein (HaHBP)
JP5871798B2 (en) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント How to stimulate liver regeneration
EP2521562B1 (en) * 2010-01-08 2019-09-18 Volution Immuno Pharmaceuticals SA Ev576 for use in the treatment of viral infections of the respiratory tract
EP2545376A4 (en) 2010-03-11 2013-08-28 Univ Louisville Res Found Methods of predicting and decreasing the risk of pregnancy loss
WO2012078968A2 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
US8961981B2 (en) * 2011-06-20 2015-02-24 Saint Louis University Targeting the neuromuscular junction for treatment
CN103796667A (en) 2011-06-22 2014-05-14 艾普莱斯制药公司 Methods of treating chronic disorders with complement inhibitors
JP6276202B2 (en) 2012-02-20 2018-02-07 スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） Polypeptide that binds to human complement C5
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
US20200325449A1 (en) 2016-06-02 2020-10-15 The Cleveland Clinic Foundation Complement inhibition for improving cell viability
MY196220A (en) 2016-06-14 2023-03-23 Regeneron Pharma Anti-C5 Antibodies and uses Thereof
WO2018193122A1 (en) 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of autoimmune blistering diseases
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2019118556A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
JP2022500389A (en) 2018-09-10 2022-01-04 ヴォリューション イミュノ ファーマシューティカルズ エスエイ Coversin for use in the treatment of rheumatic diseases
GB201905810D0 (en) 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
EP4034237A1 (en) 2019-09-27 2022-08-03 Volution Immuno Pharmaceuticals SA Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (hsct-tma)
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017099A1 (en) * 1992-02-27 1993-09-02 Merck & Co., Inc. Protein for inhibiting collagen-stimulated platelet aggregation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884066B2 (en) * 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
CA2526083C (en) * 2003-06-02 2017-01-17 Evolutec Limited Complement inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017099A1 (en) * 1992-02-27 1993-09-02 Merck & Co., Inc. Protein for inhibiting collagen-stimulated platelet aggregation

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ASGHAR S S ET AL: "Inhibition of complement by a series of substituted 2-aryl-1,3-indandiones: interaction with the fifth component of complement.", MOLECULAR IMMUNOLOGY. MAY 1986, vol. 23, no. 5, May 1986 (1986-05-01), pages 459 - 465, XP002305197, ISSN: 0161-5890 *
ASTIGARRAGA A ET AL: "Host immune response evasion strategies in Ornithodoros erraticus and O. moubata and their relationship to the development of an antiargasid vaccine.", PARASITE IMMUNOLOGY. SEP 1997, vol. 19, no. 9, September 1997 (1997-09-01), pages 401 - 410, XP008038693, ISSN: 0141-9838 *
BARANDA J A ET AL: "Purification, N-terminal sequencing and diagnostic value of the major antigens of Ornithodoros erraticus and O. moubata.", VETERINARY PARASITOLOGY. JAN 2000, vol. 87, no. 2-3, January 2000 (2000-01-01), pages 193 - 206, XP002305200, ISSN: 0304-4017 *
FEUILLARD J ET AL: "Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA).", AGENTS AND ACTIONS. MAR 1991, vol. 32, no. 3-4, March 1991 (1991-03-01), pages 343 - 346, XP000803834, ISSN: 0065-4299 *
KELLER P M ET AL: "Cloning of the cDNA and expression of moubatin, an inhibitor of platelet aggregation.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 15 MAR 1993, vol. 268, no. 8, 15 March 1993 (1993-03-15), pages 5450 - 5456, XP002305201, ISSN: 0021-9258 *
MANS B J ET AL: "Identification of putative proteins involved in granule biogenesis of tick salivary glands.", ELECTROPHORESIS. MAY 2001, vol. 22, no. 9, May 2001 (2001-05-01), pages 1739 - 1746, XP002305203, ISSN: 0173-0835 *
MANS BEN J ET AL: "Pathogenic mechanisms of sand tampan toxicoses induced by the tick, Ornithodoros savignyi.", TOXICON : OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY ON TOXINOLOGY. JUL 2002, vol. 40, no. 7, July 2002 (2002-07-01), pages 1007 - 1016, XP002305202, ISSN: 0041-0101 *
MCKENZIE R ET AL: "Regulation of complement activity by vaccinia virus complement-control protein.", THE JOURNAL OF INFECTIOUS DISEASES. DEC 1992, vol. 166, no. 6, December 1992 (1992-12-01), pages 1245 - 1250, XP008038345, ISSN: 0022-1899 *
WHITE K L JR ET AL: "Suppression of mouse complement activity by contaminants of technical grade pentachlorophenol.", AGENTS AND ACTIONS. JUL 1985, vol. 16, no. 5, July 1985 (1985-07-01), pages 385 - 392, XP008038344, ISSN: 0065-4299 *

Also Published As

Publication number Publication date
BRPI0410876B1 (en) 2020-11-03
US20070141573A1 (en) 2007-06-21
EP1629098B1 (en) 2009-04-01
DE602004020334D1 (en) 2009-05-14
BRPI0410876A (en) 2006-07-04
US20110263482A1 (en) 2011-10-27
CA2526083A1 (en) 2004-12-09
MXPA05012880A (en) 2006-02-22
JP2007536894A (en) 2007-12-20
US8993264B2 (en) 2015-03-31
US20220363726A1 (en) 2022-11-17
NZ544163A (en) 2009-06-26
AU2004242759A1 (en) 2004-12-09
US20180127472A1 (en) 2018-05-10
EP1629098A2 (en) 2006-03-01
US9834585B2 (en) 2017-12-05
WO2004106369A2 (en) 2004-12-09
ATE427356T1 (en) 2009-04-15
JP4772667B2 (en) 2011-09-14
US20160096870A1 (en) 2016-04-07
AU2004242759B2 (en) 2009-11-26
US7884188B2 (en) 2011-02-08
ES2324993T3 (en) 2009-08-21
BRPI0410876B8 (en) 2023-01-24
CA2526083C (en) 2017-01-17
HK1085511A1 (en) 2006-08-25

Similar Documents

Publication Publication Date Title
WO2004106369A3 (en) Complement inhibitors from ticks
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2005055932A3 (en) Therapeutic combinations and methods including irm compounds
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
HK1091209A1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
WO2003105840A3 (en) Sphingosine kinase inhibitors
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
MXPA05012812A (en) Compounds, methods and pharmaceutical compositions for inhibiting parp.
WO2005030791A3 (en) Isoquinolinone potassium channel inhibitors
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004041269A3 (en) New use for pharmaceutical composition
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
WO2006128143A3 (en) Hydantoin compounds
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2004105737A3 (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
EP1553951A4 (en) Methods of using and compositions comprising a jnk inhibitor for the treatment, prevention, management and/or modification of pain
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
ZA200502464B (en) Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome.
WO2003011222A3 (en) Thrombin inhibitors
WO2004060878A3 (en) Inhibitors of phosphatases
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004242759

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2526083

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004735758

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/012880

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2004242759

Country of ref document: AU

Date of ref document: 20040602

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006508386

Country of ref document: JP

Ref document number: 20048151788

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004242759

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 544163

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2004735758

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0410876

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2007141573

Country of ref document: US

Ref document number: 10558937

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10558937

Country of ref document: US